Traction in Type 1 Diabetes Patients
More and more people are taking GLP-1 receptor agonist medications like Ozempic. Specifically, these drugs have FDA approval for Type 2 diabetes and obesity. However, patients with Type 1 diabetes are also increasingly using them against their approved use for Type 2 diabetes.
While many aim to lose weight and regulate their blood sugar levels, evidence still lacks on their benefits. Still, the drugs continue to grow in popularity.
Off-Label Use: Type 1 Diabetes
Obesity rates are climbing among people with Type 1 diabetes. As a result, doctors and patients are looking for new weight-loss solutions.
A study published in the journal Diabetes, Obesity, and Metabolism looked at the medical records of over 200,000 people. Specifically, they reviewed the records of Type 1 diabetes patients from 2008 to 2023.
During this timeframe, obesity rates climbed most remarkably among patients 2 to 19 years old, from 18 to 26 percent. Meanwhile, among adults, it surged from 30 to 38 percent.
In particular, GLP-1 drugs promise appetite control and lower blood sugar. Therefore, they’ve become appealing to those struggling with both weight and glucose management. Nevertheless, despite these benefits, evidence supporting their use in Type 1 diabetes is still limited.
Although not approved for this use, many patients report positive outcomes. For instance, they claim GLP-1 has helped them control the rapid spikes and dips in their blood sugar levels. Additionally, they say the drugs have helped them shed pounds.
Still, off-label use poses serious risks. Overall, without proper guidelines, this surge could lead to dangerous consequences.
Risks Outweigh Rewards—For Now
Experts warn that GLP-1 drugs may cause hypoglycemia when paired with insulin. Moreover, some patients experience dangerous swings in blood sugar.
A recent CNN article highlighted that adverse effects like nausea, vomiting, and even diabetic ketoacidosis are not uncommon.
In short, the risks may outweigh the potential benefits. Therefore, careful medical oversight is crucial.
Doctors Urge Caution
Many endocrinologists remain skeptical of prescribing GLP-1s to Type 1 patients. They emphasize that clinical trials have not proven these drugs safe or effective in this group.
However, some do acknowledge the benefits to certain patients, who take GLP-1 along with insulin.
“Most endocrinologists nowadays do understand that people with type 1 diabetes – not everyone, but some, would benefit,” explained Dr. Viral Shah, speaking to CNN.
Still, some warn of long-term metabolic harm. Thus, they urge more research before expanding use. Until more data is available, doctors suggest sticking to approved treatments. Specifically, information from randomized, double-blind studies will be vital.
“We really need the clinical trial data dedicated for this type 1 diabetes population and see whether this is effective and safe in this population,” emphasized the study’s author, Dr. Jung-Im Shin.
Mixed Picture
Despite warnings, some patients with Type 1 diabetes say GLP-1 drugs helped them lose weight and stabilize blood sugar.
On the other hand, others report fatigue, nausea, or dangerous lows. These mixed results highlight the need for more education and monitoring. Therefore, patients should discuss options thoroughly with their healthcare provider.
Image by pikisuperstar on Freepik
